The DOI matches its OpenAlex record; 7 of the 7 references it cites were found in a registry or an index.
The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis
Abstract
The formation of a new blood supply, angiogenesis, is an essential component of carcinogenesis and unrestricted tumor growth. A substance capable of inhibiting angiogenesis would be of considerable therapeutic potential in the treatment of cancer. We previously reported that the 16-kilodalton N-terminal fragment of rat PRL (16K rPRL) was a potent inhibitor of capillary endothelial cell proliferation via a novel receptor. We now report that the nanomolar concentrations of recombinant human 16K PRL inhibit basal and basic fibroblast growth factor- or vascular endothelial growth factor-stimulated growth of bovine brain capillary endothelial cells. 16K human (h) PRL also inhibits stimulation of human umbilical vein endothelial cell proliferation by basic fibroblast growth factor. The organization of endothelial cells into capillary-like structures in type I collagen gels is also prevented by 16K hPRL. Furthermore, in an in vivo assay, the chick embryo chorioallantoic membrane assay, 16K hPRL as well as 16K rPRL were potent inhibitors of capillary formation. 16K hPRL, like 16K rPRL, maintains its biological activity as a partial PRL agonist at PRL receptors on mammary gland epithelial cells. These data demonstrate for the first time that the biological activity of 16K rPRL is not unique and that similar fragments of hPRL are active. The antiangiogenic activity of these molecules is conserved across avian and mammalian species. That 16K hPRL is a potent antiangiogenic factor in in vitro and an in vivo assay raises the exciting potential of this peptide being capable of inhibiting tumor growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986
Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α
Leibovich, S. J., Polverini, P. J., Shepard, H. M., Wiseman, D. M., Shively, V., & Nuseir, N. (1987) · Nature · doi:10.1038/329630a0 · Cited by 1,210
Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells
Fett, J. W., Strydom, D. J., Lobb, R. R., Alderman, E. M., Bethune, J. L., Riordan, J. F., & Vallee, B. L. (1985) · Biochemistry · doi:10.1021/bi00341a030 · Cited by 923
Esch, F., Baird, A., Ling, N., Ueno, N., Hill, F., Denoroy, L., Klepper, R., Gospodarowicz, D., Böhlen, P., & Guillemin, R. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6507 · Cited by 693
A New Class of Steroids Inhibits Angiogenesis in the Presence of Heparin or a Heparin Fragment
Crum, R., Szabo, S., & Folkman, J. (1985) · Science · doi:10.1126/science.2416056 · Cited by 488
Yang, E. Y., & Moses, H. L. (1990) · The Journal of cell biology · doi:10.1083/jcb.111.2.731 · Cited by 464
The angiogenic activity of the fibroblast and epidermal growth factor
Gospodarowicz, D., Bialecki, H., & Thakral, T. K. (1979) · Experimental Eye Research · doi:10.1016/0014-4835(79)90038-1 · Cited by 260
Cited by
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
O'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345
Prolactin: structure, function, and regulation of secretion
Freeman, M. E., Kanyicska, B., Lerant, A., & Nagy, G. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.4.1523 · Cited by 2,457
Clinical Applications of Research on Angiogenesis
Folkman, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332608 · Cited by 2,264
The implications of angiogenesis for the biology and therapy of cancer metastasis
Fidler, I. (1994) · Cell · doi:10.1016/0092-8674(94)90187-2 · Cited by 1,098
Angiogenesis and Tumor Metastasis
Zetter, B. R. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.407 · Cited by 1,015
Tumor angiogenesis: past, present and the near future
Kerbel, R. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.505 · Cited by 976
VEGF is required for growth and survival in neonatal mice
Gerber, H.-P., Hillan, K. J., Ryan, A. M., Kowalski, J., Keller, G.-A., Rangell, L., Wright, B. D., Radtke, F., Aguet, M., & Ferrara, N. (1999) · Development · doi:10.1242/dev.126.6.1149 · Cited by 915
The Role of Prolactin in Mammary Carcinoma
Clevenger, C. V., Furth, P. A., Hankinson, S. E., & Schuler, L. A. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0036 · Cited by 545
Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects
Battegay, E. J. (1995) · Journal of Molecular Medicine · doi:10.1007/bf00192885 · Cited by 537
What Can We Learn from Rodents about Prolactin in Humans?
Ben-Jonathan, N., LaPensee, C. R., & LaPensee, E. W. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0017 · Cited by 523
(1996) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60862-3 · Cited by 510
Secreted cathepsin L generates endostatin from collagen XVIII
Felbor, U. (2000) · The EMBO Journal · doi:10.1093/emboj/19.6.1187 · Cited by 469
Structural Variants of Prolactin: Occurrence and Physiological Significance
SINHA, Y. N. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-354 · Cited by 433
Prolactin: The New Biology of an Old Hormone
Goffin, V., Binart, N., Touraine, P., & Kelly, P. A. (2002) · Annual Review of Physiology · doi:10.1146/annurev.physiol.64.081501.131049 · Cited by 416
Angiogenesis and angiogenesis inhibition: An overview
Folkman, J. (1997) · Experientia Supplementum · doi:10.1007/978-3-0348-9006-9_1 · Cited by 410
Molecular Mechanisms of Coronary Collateral Vessel Growth
Schaper, W., & Ito, W. D. (1996) · Circulation Research · doi:10.1161/01.res.79.5.911 · Cited by 371
Kringle Domains of Human Angiostatin
Cao, Y., Ji, R. W., Davidson, D., Schaller, J., Marti, D., Söhndel, S., McCance, S. G., O'Reilly, M. S., Llinás, M., & Folkman, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.29461 · Cited by 368
Mathematical modeling of tumor-induced angiogenesis
Mantzaris, N. V., Webb, S., & Othmer, H. G. (2004) · Journal of Mathematical Biology · doi:10.1007/s00285-003-0262-2 · Cited by 362
In Vitro Models of Vasculogenesis and Angiogenesis
Vailhé, B., Vittet, D., & Feige, J.-J. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780252 · Cited by 357
Antiangiogenic therapy of transgenic mice impairs de novo tumor growth.
Parangi, S., O'Reilly, M., Christofori, G., Holmgren, L., Grosfeld, J., Folkman, J., & Hanahan, D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.5.2002 · Cited by 344
Sasaki, T. (1998) · The EMBO Journal · doi:10.1093/emboj/17.15.4249 · Cited by 332
Angiogenesis inhibition: A review
Auerbach, W., & Auerbach, R. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90027-2 · Cited by 321
Vasostatin, a Calreticulin Fragment, Inhibits Angiogenesis and Suppresses Tumor Growth
Pike, S. E., Yao, L., Jones, K. D., Cherney, B., Appella, E., Sakaguchi, K., Nakhasi, H., Teruya-Feldstein, J., Wirth, P., Gupta, G., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2349 · Cited by 310
Plasma Prolactin Levels and Subsequent Risk of Breast Cancer in Postmenopausal Women
Hankinson, S. E., Willett, W. C., Michaud, D. S., Manson, J. E., Colditz, G. A., Longcope, C., Rosner, B., & Speizer, F. E. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.629 · Cited by 297
Sieczkiewicz, G. J., Hussain, M., & Kohn, E. C. (2002) · Ovarian Cancer · doi:10.1007/978-1-4757-3587-1_17 · Cited by 295
GOFFIN, V., SHIVERICK, K. T., KELLY, P. A., & MARTIAL, J. A. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-4-385 · Cited by 293
Self-citationKringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth
Cao, Y., Chen, A., An, S. S. A., Ji, R.-W., Davidson, D., Cao, Y., & Llinás, M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22924 · Cited by 293
The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin
Gately, S., Twardowski, P., Stack, M. S., Cundiff, D. L., Grella, D., Castellino, F. J., Enghild, J., Kwaan, H. C., Lee, F., Kramer, R. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10868 · Cited by 292
Cheng, W.-F., Hung, C.-F., Chai, C.-Y., Hsu, K.-F., He, L., Ling, M., & Wu, T.-C. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12346 · Cited by 281
Struman, I., Bentzien, F., Lee, H., Mainfroid, V., D’Angelo, G., Goffin, V., Weiner, R. I., & Martial, J. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1246 · Cited by 279
Self-citationSignaling via Vascular Endothelial Growth Factor Receptors
Petrova, T. V., Makinen, T., & Alitalo, K. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4707 · Cited by 277
Angiogenesis in Endocrine Tumors
Turner, H. E., Harris, A. L., Melmed, S., & Wass, J. A. H. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0008 · Cited by 275
O'Reilly, M. S., Wiederschain, D., Stetler-Stevenson, W. G., Folkman, J., & Moses, M. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.41.29568 · Cited by 272
Corbacho, A., Martinez De La Escalera, G., & Clapp, C. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1730219 · Cited by 256
Self-citationThe role of the prolactin/vasoinhibin axis in rheumatoid arthritis: An integrative overview
Clapp, C., Adán, N., Ledesma-Colunga, M. G., Solís-Gutiérrez, M., Triebel, J., & Martínez de la Escalera, G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2187-0 · Cited by 38
Self-citation
Metadata
- Authors
- Clapp, C., MARTIAL, J. A., Guzman, R. C., Rentier-Delure, F., & Weiner, R. I.
- Venue
- Endocrinology
- Publisher
- Oxford University Press
- Published
- 1993-09-01
- Volume
- 133
- Issue
- 3
- Pages
- 1292-1299
- ISSN
- 0013-7227 (ISSN-L)
- OpenAlex
- W2011614963
- Cited by
- 340
- References
- 7
- FWCI
- 3.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.